UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evidence for a very-long-term trend in geomagnetic secular variation

Nature geoscience, 2008-06, Vol.1 (6), p.395-398

2008

Volltextzugriff (PDF)

The intensity of the geomagnetic field in the late-Archaean: new measurements and an analysis of the updated IAGA palaeointensity database

Earth, planets, and space, 2009-01, Vol.61 (1), p.9-22

2009

Volltextzugriff (PDF)

Evidence for a very-long-term trend in geomagnetic secular variation

Nature geoscience, 2008-06, Vol.1 (6), p.395-398

2008

Volltextzugriff (PDF)

Palaeomagnetism of flood basalts in the Pilbara Craton, Western Australia: Late Archaean continental drift and the oldest known reversal of the geomagnetic field

Journal of Geophysical Research - Solid Earth, 2003-12, Vol.108 (B12), p.2551-n/a

2003

Volltextzugriff (PDF)

The intensity of the geomagnetic field in the late-Archaean: new measurements and an analysis of the updated IAGA palaeointensity database: Magnetic of Volcanic Materials - Tribute to Works of Michel Prévot

Earth, planets, and space, 2009, Vol.61 (1), p.9-22

2009

Volltextzugriff (PDF)

Palaeomagnetism of flood basalts in the Pilbara Craton, Western Australia: Late Archaean continental drift and the oldest known reversal of the geomagnetic field

Journal of geophysical research, 2003, Vol.108 (B12), p.EPM2.1-EPM2.21

2003

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis

Clinical pharmacokinetics, 2019-01, Vol.58 (1), p.15-37

2019

Volltextzugriff (PDF)

Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial

Scandinavian journal of gastroenterology, 2021-02, Vol.56 (2), p.145-154

2021

Volltextzugriff (PDF)

Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients

Scandinavian journal of gastroenterology, 2019-04, Vol.54 (4), p.453-458

2019

Volltextzugriff (PDF)

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease

Inflammatory bowel diseases, 2017-04, Vol.23 (4), p.650-660

2017

Volltextzugriff (PDF)

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

Therapeutic drug monitoring, 2018-04, Vol.40 (2), p.202-211

2018

Volltextzugriff (PDF)

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples

Therapeutic drug monitoring, 2020-04, Vol.42 (2), p.289-294

2020

Volltextzugriff (PDF)

Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study

Scandinavian journal of gastroenterology, 2019-06, Vol.54 (6), p.700-706

2019

Volltextzugriff (PDF)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report

Clinical case reports, 2019-11, Vol.7 (11), p.2049-2053

2019

Volltextzugriff (PDF)

Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

Cochrane database of systematic reviews, 2018-07, Vol.2018 (7)

2018

Volltextzugriff (PDF)

Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S392-S392

2017

Volltextzugriff (PDF)

Is attention deficit/hyperactivity disorder among men associated with initiation or escalation of substance use at 15-month follow-up? A longitudinal study involving young Swiss men

Addiction (Abingdon, England), 2016-10, Vol.111 (10), p.1867-1878

2016

Volltextzugriff (PDF)

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

The lancet. Gastroenterology & hepatology, 2018-06, Vol.3 (6), p.404-412

2018

Volltextzugriff (PDF)

Tu1822 – Ifx Serum Levels At Trough Do Not Adequately Reflect Exposure in IBD Patients

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1137-S-1138

2019

Volltextzugriff (PDF)

Underestimation of Fecal Loss of Infliximab due to Proteolysis

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S388-S389

2017

Volltextzugriff (PDF)

Golimumab for moderate to severe ulcerative colitis

Expert review of gastroenterology & hepatology, 2017-05, Vol.11 (5), p.401-406

2017

Volltextzugriff (PDF)

695 Insufficient Infliximab Exposure Predisposes to Immunogenicity and Enhanced Clearance of Infliximab in IBD

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S144-S144

2016

Volltextzugriff (PDF)

250 - Unchanged Infliximab Serum Concentrations After Switching from the Originator Infliximab to the Biosimilar CT-P13 in Patients with Quiescent Crohn's Disease: A Prospective Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S66-S66

2017

Volltextzugriff (PDF)

Is attention deficit/hyperactivity disorder among men associated with initiation or escalation of substance use at 15-month follow-up? A longitudinal study involving young Swiss men: ADHD and substance use

Addiction (Abingdon, England), 2016-10, Vol.111 (10), p.1867-1878

2016

Volltextzugriff (PDF)

Sa1915 - Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S392-S392

2017

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(27)
Buchkapitel
(1)

Sprache

Englisch
(28)
Japanisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Evidence for a very-long-term trend in geomagnetic secular variation

The intensity of the geomagnetic field in the late-Archaean: new measurements and an analysis of the updated IAGA palaeointensity database

Evidence for a very-long-term trend in geomagnetic secular variation

Palaeomagnetism of flood basalts in the Pilbara Craton, Western Australia: Late Archaean continental drift and the oldest known reversal of the geomagnetic field

The intensity of the geomagnetic field in the late-Archaean: new measurements and an analysis of the updated IAGA palaeointensity database: Magnetic of Volcanic Materials - Tribute to Works of Michel Prévot

Palaeomagnetism of flood basalts in the Pilbara Craton, Western Australia: Late Archaean continental drift and the oldest known reversal of the geomagnetic field

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis

Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial

Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples

Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report

Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

Is attention deficit/hyperactivity disorder among men associated with initiation or escalation of substance use at 15-month follow-up? A longitudinal study involving young Swiss men

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Tu1822 – Ifx Serum Levels At Trough Do Not Adequately Reflect Exposure in IBD Patients

Underestimation of Fecal Loss of Infliximab due to Proteolysis

Golimumab for moderate to severe ulcerative colitis

695 Insufficient Infliximab Exposure Predisposes to Immunogenicity and Enhanced Clearance of Infliximab in IBD

250 - Unchanged Infliximab Serum Concentrations After Switching from the Originator Infliximab to the Biosimilar CT-P13 in Patients with Quiescent Crohn's Disease: A Prospective Study

Is attention deficit/hyperactivity disorder among men associated with initiation or escalation of substance use at 15-month follow-up? A longitudinal study involving young Swiss men: ADHD and substance use

Sa1915 - Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

Suchergebnisse filtern